Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
MannKind
NasdaqGM:MNKD Community
1
Narratives
written by author
1
Comments
on narratives written by author
9
Fair Values set
on narratives written by author
Create a narrative
MannKind
Popular
Undervalued
Overvalued
MannKind
WA
Analyst Price Target
Consensus Narrative from 6 Analysts
Technosphere Platform Will Enable New Inhaled Therapies For Unmet Needs
Key Takeaways Promising pipelines and product innovations could boost future revenues significantly, addressing unmet medical needs and improving margins. Strategic collaborations and focused operational growth efforts aim to enhance revenue and earnings through efficiencies and market expansions.
View narrative
US$9.80
FV
41.2% undervalued
intrinsic discount
15.68%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
24 days ago
author updated this narrative
Your Valuation for
MNKD
MannKind
Your Fair Value
US$
Current Price
US$5.76
22.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-216m
523m
2015
2018
2021
2024
2025
2027
2030
Revenue US$522.8m
Earnings US$42.2m
Advanced
Set as Fair Value